Julie Matthews
Julie’s next role was at Orphan Europe in Paris as Head of Clinical Development and Regional Business Manager, before going on to set up and run the company’s UK affiliate as General Manager responsible for drug and business development, regulatory affairs, sales and marketing.
Julie co-founded TMC in 2000.
Carol Woodward
Carol has extensive experience across many therapeutic areas, particularly oncology and all development phases. She has held roles in both Pharma companies and Clinical Research Organisations, including senior positions such as the Global Therapeutic Head of Haematology/Oncology at PPD and Vice President Development Innovations and European Operations at Sarah Cannon.
Carol joined TMC in March 2020.
Stewart Sharpe
Stewart has a wealth of expertise gained across a variety of specialty, rare/orphan and specialist diseases: hepatology, metabolic diseases, CV, GI, HIV, oncology, transplantation and respiratory. Previously, he held senior global roles with Syneos Health, Intercept, Circassia, OSI Pharmaceuticals, Johnson & Johnson, Novartis, Roche and GSK. He also served as Deputy Chair and non-executive director on the board of the UK’s Oxford Biosciences Network (OBN).
Stewart joined TMC in June 2023
Marcelo Vaz
Marcelo developed clinical research expertise across the range of respiratory diseases, including COPD, Asthma, Lung Cancer, Cystic Fibrosis, Respiratory infections, Sepsis, mechanical ventilation, ARDS and SIRS.
Other areas of clinical research experience include CV, TGI, rheumatology, woman’s health, oncology, ENT, CNS, DM. His rare diseases expertise includes supporting strategic creation of drug development plans, protocol concepts, and moving from classic to adaptive study designs.
Marcelo joined TMC in 2022.
Catherine Moncad
Catherine has held regulatory roles at Smith & Nephew and PRA, gaining extensive experience in OTCs, generics, devices, prescription pharmaceuticals and wide clinical trial experience.
Since joining TMC, she heads the Regulatory Services team that supports clients with all stages of drug development from early non-clinical, through to clinical, to licence applications and even post-approval support.
Catherine joined TMC in March 2017.
Andrew Green
Andrew started his career in a variety of roles including a significant period as a Junior Partner in accounting practice.
In November 1998 Andrew joined Quintiles and has since had a varied career working in most of the service lines, including Clinical Operations, Centralised Monitoring, Data Sciences, Safety and Regulatory where he gained Orphan Drug experience, and therapy areas including Oncology, Cardiovascular and CNS.
Andrew has supported annual revenues of up to $1bn and teams of up to 9000 staff across the world.
He is a Fellow of the ACCA.
Andrew joined TMC in November 2021.
Quentin Clarke
Quentin has vast experience in both pre-and post- marketing PV surveillance and case management. His very broad experience of course encompasses managing PSMFs, EU and local RMP documents, periodic reports etc. as well as signal detection /review processes.
Quentin joined TMC in 2020.
Dr Victoria Datsenko
A medically qualified doctor, her extensive experience covers all clinical trial phases across a broad range of indications and therapies with particular expertise in oncology and cell therapy.
Victoria’s Clinical Services team comprises experienced and highly capable Project Directors, Project Managers, CRAs and CTAs allowing her direct oversight and governance of all aspects of our clinical projects.
Victoria joined TMC in 2022.